Loading provider…
Loading provider…
Ophthalmology Physician in Newport Beach, CA
NPI: 1255435822Primary Practice Location
David L. Wirta M.D. Inc.
520 Superior Ave, Newport Beach, CA
Primary Employer
David L. Wirta M.D. Inc.
drwirta.com
HQ Phone
Get MD David's Phone Numberphone_androidMobile
Get MD David's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
OR State Medical License
1997
CA State Medical License
1995 - 2026

American Board of Ophthalmology
Ophthalmology
UCLA David Geffen School of Medicine/UCLA Medical Center/UCLA Stein and Doheny Eye Institutes
Residency • Ophthalmology
1994 - 1997
Los Angeles County-Harbor-UCLA Medical Center
Internship • Transitional Year
1993 - 1994
David Geffen School of Medicine at UCLA
medschool.ucla.edu
Medical School
Until 1993
Repository Corticotropin Injection (Acthar® Gel) for Refractory Severe Noninfectious Keratitis: Efficacy and Safety from a Phase 4, Multicenter, Open-Label Study.
Authors: David Wirta, Eugene Mclaurin, George Ousler, Jingyu Liu, R Kacmaz, Joseph Grieco
Publication Date: 2021-07-23
Reversal of Pharmacologically Induced Mydriasis with Phentolamine Ophthalmic Solution.
Authors: Pepose, Jay S, Wirta, David, Evans, David, Withers, Barbara, Rahmani, Kavon, Lazar, Audrey, Coleman, Drey, Patel, Ronil, Jaber, Reda, Sooch, Mina, Brigell, Mitchell, Charizanis, Konstantinos
Journal: Ophthalmology
Publication Date: 2024-09-16
Lead Sponsor: Aerie Pharmaceuticals
Intervention / Treatment: DRUG: AR-15512 Ophthalmic Solution, DRUG: AR-15512 Ophthalmic Solution Vehicle
Lead Sponsor: Surface Ophthalmics, Inc.
Intervention / Treatment: DRUG: Lifitegrast 5% Ophthalmic Solution, DRUG: SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate), DRUG: Mycophenolic Acid 0.1%, DRUG: Mycophenolic Acid 0.3%, DRUG: Betamethasone Sodium Phosphate 0.01%, DRUG: Placebo Comparator: Vehicle, DRUG: Cyclosporine 0.05% Ophthalmic Emulsion
Lead Sponsor: Tarsus Pharmaceuticals, Inc.
Intervention / Treatment: DRUG: TP-03 Vehicle, DRUG: TP-03, 0.25%